CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
XENOTHERA is developing a treatment for COVID-19 using Glyco-Humanized Polyclonal Antibodies, specifically targeting patients with moderate to severe pneumonia. The project aims to conduct clinical trials to demonstrate the efficacy of the treatment.
Since 2014 XENOTHERA has developed a platform for producing Glyco-Humanized Polyclonal Antibodies (GH-pAb) with high efficiency and optimized safety.
It has been known for decades that polyclonal antibodies are very efficient weapons in infectious diseases, either bacterial or viral, and they are established as superior to monoclonal in various viral infections.Since the beginning of the pandemic XENOTHERA has initiated a project to develop a new treatment against COVID-19 based on its technolog…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
